FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810790882> ?p ?o ?g. }

• W2810790882 abstract "The objective of cancer immunotherapy is to prime the host's immune system to recognize and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited potent antitumor effects in the murine syngeneic A20 lymphoma and the CT26 colon carcinoma models. IMO‑2125 exhibited superior A20 antitumor activity when injected intratumorally (i.t.) compared with equivalent subcutaneous doses. In mice bearing dual CT26 grafts, the i.t. injection of right flank tumors elicited infiltration of cluster of differentiation (CD)3+ T lymphocytes into tumors, resulting in the regression of injected and uninjected left flank tumors. Depletion of CD8+, but not CD4+, T‑cells abrogated the IMO‑2125‑mediated antitumor response, suggesting that CD8+ lymphocytes are required for the antitumor activity. In mice harboring right flank CT26 and left flank β‑galactosidase (β‑gal)‑expressing CT26.CL25 grafts, the i.t. administration of IMO‑2125 to the CT26 graft resulted in potent and dose‑dependent antitumor activity against the two grafts. Splenic T‑cells isolated from these mice responded to AH1 antigen (present in the two tumors) and β‑gal antigen (present only in CT26.CL25) in an interferon γ enzyme‑linked immunospot assay, suggesting the clonal expansion of T‑cells directed against antigens from the two tumors. Mice with ablated CT26 tumors by previous IMO‑2125 treatment rejected re‑implanted CT26 tumor cells, but not A20 tumor cells, demonstrating that the initial IMO‑2125 treatment created a long‑lived tumor‑specific immune memory of CT26 antigens. A quantitative increase in CD3+ T lymphocytes in injected A20 tumors and an upregulation of selected checkpoint genes, including indoleamine 2,3‑dioxygenase (IDO)‑1, IDO‑2, programmed cell death protein-1 (PD-1); programmed cell death protein ligand 1 (PD-L1), carcinoembryonic antigen‑related cell adhesion molecule 1, tumor necrosis factor receptor superfamily member 4 (OX40), OX40 ligand, T‑cell immunoglobulin and mucin‑domain‑containing 3 protein, lymphocyte‑activation gene 3, cytotoxic T‑lymphocyte‑associated protein 4, were observed following IMO‑2125 treatment. IMO‑2125 also increased immune checkpoint gene expression in injected and uninjected contralateral CT26 tumors, suggesting that the co‑administration of anti‑CTLA‑4, anti‑PD‑1 or anti‑PD‑L1 therapies with IMO‑2125 may provide additional therapeutic efficacy." @default.
• W2810790882 created "2018-07-10" @default.
• W2810790882 creator A5010223990 @default.
• W2810790882 creator A5021230787 @default.
• W2810790882 creator A5067885487 @default.
• W2810790882 creator A5069014764 @default.
• W2810790882 creator A5073741821 @default.
• W2810790882 date "2018-06-27" @default.
• W2810790882 modified "2023-09-28" @default.
• W2810790882 title "Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy" @default.
• W2810790882 cites W1514540900 @default.
• W2810790882 cites W1574264971 @default.
• W2810790882 cites W1967115584 @default.
• W2810790882 cites W1975992327 @default.
• W2810790882 cites W1981015419 @default.
• W2810790882 cites W1998686998 @default.
• W2810790882 cites W2005695087 @default.
• W2810790882 cites W2005929643 @default.
• W2810790882 cites W2009097375 @default.
• W2810790882 cites W2012489369 @default.
• W2810790882 cites W2016789384 @default.
• W2810790882 cites W2018224938 @default.
• W2810790882 cites W2023955378 @default.
• W2810790882 cites W2033043498 @default.
• W2810790882 cites W2038708057 @default.
• W2810790882 cites W2042017272 @default.
• W2810790882 cites W2045167121 @default.
• W2810790882 cites W2047366876 @default.
• W2810790882 cites W2049999948 @default.
• W2810790882 cites W2056628849 @default.
• W2810790882 cites W2057577614 @default.
• W2810790882 cites W2065157325 @default.
• W2810790882 cites W2066671159 @default.
• W2810790882 cites W2074851687 @default.
• W2810790882 cites W2090640877 @default.
• W2810790882 cites W2091905924 @default.
• W2810790882 cites W2092018061 @default.
• W2810790882 cites W2096322385 @default.
• W2810790882 cites W2096461956 @default.
• W2810790882 cites W2105117087 @default.
• W2810790882 cites W2105169654 @default.
• W2810790882 cites W2107277218 @default.
• W2810790882 cites W2109450812 @default.
• W2810790882 cites W2114403343 @default.
• W2810790882 cites W2119684232 @default.
• W2810790882 cites W2121314233 @default.
• W2810790882 cites W2140724157 @default.
• W2810790882 cites W2149118203 @default.
• W2810790882 cites W2161228679 @default.
• W2810790882 cites W2166586819 @default.
• W2810790882 cites W2302088846 @default.
• W2810790882 cites W2409912500 @default.
• W2810790882 cites W2412250098 @default.
• W2810790882 cites W2417414132 @default.
• W2810790882 cites W2534168737 @default.
• W2810790882 cites W2613990808 @default.
• W2810790882 cites W2618764609 @default.
• W2810790882 cites W2677916979 @default.
• W2810790882 cites W2741276440 @default.
• W2810790882 cites W2763799406 @default.
• W2810790882 cites W3192944769 @default.
• W2810790882 cites W4328001753 @default.
• W2810790882 doi "https://doi.org/10.3892/ijo.2018.4456" @default.
• W2810790882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29956749" @default.
• W2810790882 hasPublicationYear "2018" @default.
• W2810790882 type Work @default.
• W2810790882 sameAs 2810790882 @default.
• W2810790882 citedByCount "37" @default.
• W2810790882 countsByYear W28107908822018 @default.
• W2810790882 countsByYear W28107908822019 @default.
• W2810790882 countsByYear W28107908822020 @default.
• W2810790882 countsByYear W28107908822021 @default.
• W2810790882 countsByYear W28107908822022 @default.
• W2810790882 countsByYear W28107908822023 @default.
• W2810790882 crossrefType "journal-article" @default.
• W2810790882 hasAuthorship W2810790882A5010223990 @default.
• W2810790882 hasAuthorship W2810790882A5021230787 @default.
• W2810790882 hasAuthorship W2810790882A5067885487 @default.
• W2810790882 hasAuthorship W2810790882A5069014764 @default.
• W2810790882 hasAuthorship W2810790882A5073741821 @default.
• W2810790882 hasBestOaLocation W28107908821 @default.
• W2810790882 hasConcept C121608353 @default.
• W2810790882 hasConcept C126322002 @default.
• W2810790882 hasConcept C147483822 @default.
• W2810790882 hasConcept C154317977 @default.
• W2810790882 hasConcept C167672396 @default.
• W2810790882 hasConcept C202751555 @default.
• W2810790882 hasConcept C203014093 @default.
• W2810790882 hasConcept C2776107976 @default.
• W2810790882 hasConcept C2776662205 @default.
• W2810790882 hasConcept C2777701055 @default.
• W2810790882 hasConcept C2780674031 @default.
• W2810790882 hasConcept C502942594 @default.
• W2810790882 hasConcept C55493867 @default.
• W2810790882 hasConcept C71924100 @default.
• W2810790882 hasConcept C86803240 @default.
• W2810790882 hasConcept C8891405 @default.
• W2810790882 hasConceptScore W2810790882C121608353 @default.
• W2810790882 hasConceptScore W2810790882C126322002 @default.
• W2810790882 hasConceptScore W2810790882C147483822 @default.

• next